Stock Evaluator: Smith & Nephew plc (SNN)

Smith & Nephew plc SNN

$31.56 -0.77 -2.38%
July 31, 2026 4:00:02 PM EST November 10, 2021 Volume: 1,842,852
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NYSE | DELAYED PRICE
SECTOR INDUSTRY
Health Care Health Care Equipment & Supplies

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Commentary & Analysis


Financial Summary

Share Statistics SNN Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $13,335.2 $334.8 81%
Shares Out (Mil) 866.1 41.7 93%
Institutional Ownership 99.9% 77.3% 96%
Float (Mil) 831.4 34.7 90%
Beta 0.67 0.86 39%
Avg Daily Volume (000s) 1,890 266 81%
Price Change
(52-week)
2.3% 60.7% 47%
Growth SNN Industry
Median
Percentile
(All Stocks)
Sales (5yr) 6.2% 11.8% 42%
Net Income (5yr) 6.9% (5.8%) 50%
EPS (5yr) 6.9% 10.7% 41
Dividends (5yr) 0.8% 0.0% 66%
Cash Flow (5yr) (15.3%) (16.1%) 49%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates na na na
Current EPS na na na
Month Ago EPS na na na
# Rev Up na na na
# Rev Down na na na
Three Months Ago EPS na na na
Year/Year Chg na na na
Financials SNN Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $6,164 $152 78%
Net Income (TTM) (Mil) $625 ($11) 82%
EPS (TTM) $0.721 ($0.500) 57%
Operating Cash Flow (TTM) (Mil) $1,285 ($2) 84%
Net Cash Flow (TTM) (Mil) ($64) $1 17%
Long-Term Debt (Q1) (Mil) $3,177 $22 80%
Enterprise Value (Q1) (Mil) $15,635 $304 80%
Valuation SNN Industry
Median
Percentile
(All Stocks)
P/B 5.19 2.88 79%
P/E 45.2 30.5 82%
Dividend Yield 3.0% 0.0% 85%
PEG (5yr hist) 6.5 1.9 90%
Ratios SNN Industry
Median
Percentile
(All Stocks)
Gross Margin 68.3% 59.1% 80%
Net Margin 10.1% (7.7%) 63%
ROA 6.0% (13.7%) 76%
ROE 11.8% (15.9%) 63%
Liabilities to Assets 49.4% 44.9% 41%
F-Score 7 4 84%

Smith & Nephew plc did not pass any screens on 7/30/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors